Navigation Links
Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
Date:1/5/2012

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.  PF-05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A & B patients with inhibitors.  The IND filing and initiation of the Phase 1 clinical trial triggered additional milestone payments of $7.0 million payable to Catalyst by Pfizer under the terms of their research and license agreement. 

"We are very excited to see the lead candidate from Catalyst's hemostasis franchise advance into human clinical trials," said Nassim Usman, Ph.D., Catalyst's CEO.  "In parallel, Catalyst is independently achieving significant progress in engineering next-generation recombinant human Factor IX and Xa variants with highly differentiated advantages for the treatment of acute and prophylactic bleeding disorders, including hemophilia and non-hemophilia indications.  We are diligently executing on our goal of expanding Catalyst's high-value pipeline of novel engineered proteases." 

In June 2009 Catalyst and Wyeth LLC, now a wholly owned subsidiary of Pfizer Inc., formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second-generation Factor VIIa products.  Total payments under the collaboration, including an upfront payment of $21 million, ongoing research funding and milestone payments, could exceed $500 million, exclusive of double-digit royalty payments. 

About Catalyst Biosciences 

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that ta
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , , , , , BEIJING ... SVA),a leading China -based vaccine manufacturer, today announced that it ... of the,company in an underwritten public offering. Sinovac plans to grant ... shares,to cover overallotments. , Sinovac plans to ...
... , SAN DIEGO , Jan. 20, 2010 Amylin ... Call for the fourth quarter and full year 2009 on Wednesday, ... PT . Daniel M. Bradbury , Amylin,s president and chief executive ... release financial results for the fourth quarter and year ended December ...
Cached Medicine Technology:Sinovac Announces Plan to Launch Offering of Common Shares 2Sinovac Announces Plan to Launch Offering of Common Shares 3Amylin Pharmaceuticals to Webcast Year-End Financial Results 2
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... than 40 years away from a food shortage that ... to a top scientist at the U.S. Agency for ... food production will be limited on a global scale ... Dr. Fred Davies, senior science advisor for the agency,s ... politically destabilizing by 2050 as energy issues are today.", ...
(Date:4/17/2014)... An anti-malarial treatment that lost its status as the ... a new lease of life, with new research indicating ... findings could revive the use of the cheap anti-malarial ... which claims the lives of more than half a ... parasite that causes malaria has developed resistance to chloroquine, ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2
... 1 (HealthDay News) -- Black and Hispanic children with frequent ... care than white children, say U.S. researchers. They analyzed ... and found that each year about 4.6 million children have ... 12 months. Overall, 3.7 percent of children with frequent ...
... Alexandria, VA Racial and ethnic disparities among children with ... according to new research published in the November 2010 issue ... Ear infections are one of the most common health ... by their third birthday. Annual costs in the United States ...
... lacked a reliable screening test for it. Now researchers at ... report the PHQ-9 (Patient Health Questionnaire - 9 item) is ... Led by Laura P. Richardson, MD, MPH, the team ... 442 teenage patients, age 13-17, at Group Health. The test ...
... have developed an efficient method for extracting and archiving ... keep track of estimated radiation dose delivered to each ... informed health care decisions and improve patient safety, according ... Journal of the American College of Radiology ( www.jacr.org ...
... to designing effective drug treatments that are precisely tailored to ... any of which can trigger the body,s immune system defenses. ... the latest issue of Nature Medicine online Oct. ... three weeks can pinpoint the unique binding site or ...
... Hepatitis C patients who receive a liver from a white ... receive a liver from a black donor, researchers have found. ... a liver from a white donor, the study authors noted. ... 165 hepatitis C patients who received a liver transplant at ...
Cached Medicine News:Health News:Race, Income Affect Care for Ear Infections: Study 2Health News:Racial and ethnic disparities impact care for children with frequent ear infections 2Health News:Racial and ethnic disparities impact care for children with frequent ear infections 3Health News:Researchers develop successful method for extracting and archiving patient radiation dose info 2Health News:Immune system's bare essentials used to speedily detect drug targets 2Health News:Immune system's bare essentials used to speedily detect drug targets 3
Our smallest port is available with or without a COOK Peel-Away Introducer Set....
The mid-sized polysulfone is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 0.9 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: